News Kinnate Biopharma Inc.

Equities

KNTE

US49705R1059

Delayed Nasdaq Other stock markets 21:00:00 02/04/2024 BST			5-day change	1st Jan Change
2.65 ^USD	-0.38%		-.--%	+11.81%

04-03	Kinnate Biopharma Inc. Announces Board Resignations	CI
04-03	Kinnate Biopharma Inc.(NasdaqGS:KNTE) dropped from NASDAQ Composite Index	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Kinnate Biopharma Inc. Announces Board Resignations	04-03	CI
XOMA Corporation Announces Closing of Tender Offer	04-03	AQ
Kinnate Biopharma Inc.(NasdaqGS:KNTE) dropped from NASDAQ Composite Index	04-02	CI
XOMA Corporation completed the acquisition of Kinnate Biopharma Inc..	04-02	CI
Kinnate Biopharma Inc.(NasdaqGS:KNTE) dropped from S&P TMI Index	04-02	CI
North American Morning Briefing : Stocks Seen -2-	04-02	DJ
Kinnate Biopharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
North American Morning Briefing : Markets Steady -2-	03-26	DJ
XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.	03-19	AQ
KINNATE BIOPHARMA INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTE	03-13	BU
Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, Exarafenib, to Pierre Fabre Laboratories	03-04	AQ
Kinnate Biopharma Sells Cancer Treatment Assets to Pierre Fabre Laboratories	03-01	MT
Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, exarafenib, to Pierre Fabre Laboratories	03-01	PR
Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, Exarafenib, to Pierre Fabre Laboratories	03-01	AQ
Stifel Raises Kinnate Biopharma's Price Target to $2.59 From $1.50, Keeps Hold Rating	02-26	MT
KINNATE BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTE	02-19	BU
XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash per Share plus a Contingent Value Right	02-19	AQ
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Kinnate Biopharma Inc.	02-16	PR
Sector Update: Health Care Stocks Advance Friday Afternoon	02-16	MT
Wedbush Adjusts Kinnate Biopharma's PT to $2.34 From $2 on Heels of Announced Sale Agreement With XOMA, Keeps Neutral Rating	02-16	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Kinnate Biopharma Inc.

Equities

KNTE

US49705R1059

Summary

Filters